Trademark Overview
On Tuesday, February 11, 2025, a trademark application was filed for ARTEMETRX GENECQ with the United States Patent and Trademark Office. The USPTO has given the ARTEMETRX GENECQ trademark a serial number of 99036339. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, February 11, 2025. This trademark is owned by Edgewood Partners Insurance Center. The ARTEMETRX GENECQ trademark is filed in the Advertising, Business and Retail Services, Insurance & Financial Services, and Computer & Software Services & Scientific Services categories with the following description:
Pharmacy benefit consulting, namely, consulting services for health and pharmacy benefit plan sponsors in the field of consumer health care insurance plan options
Business consulting services; Business management consulting; Business organization consulting; Analyzing and compiling data for measuring the performance of pharmacies and pharmacy programs; Insurance claims auditing, namely, auditing of pharmacy benefit claims data; Business auditing; Forensic accounting services; Negotiations of business contracts for pharmacy benefit programs for others; Business consulting services, namely, business administration assistance with development and scoring of requests for proposals; Pharmaceutical cost management services relating to pharmaceutical drug programs for health care facilities, employers, labor unions, and health insurance plans; Business organization consulting, namely, business data analysis and reporting to provide recommendations for medication spending in pharmacy benefit plans; Pharmacy business management services, namely, analysis of business data related to market trends in medication spending for pharmacy benefit plans; Analyzin...
Providing online, non-downloadable software to access a contract pharmacy network for evaluating and monitoring performance of prescription drug programs; providing online, non-downloadable software for analyzing drug spend to facilitate enhanced cost management for plan sponsors; providing online, non-downloadable software for analyzing and predicting patient need for gene therapies to facilitate enhanced cost management for plan sponsors.
